Clinical characteristics of patients in training and validation cohorts
| Characteristic . | Training cohort (n = 174) . | Validation cohort (n = 60) . |
|---|---|---|
| Age, y | ||
| Median (range) | 55.5 (19-70) | 52.5 (20-65) |
| ≤60 | 111 (63.8) | 45 (75.0) |
| >60 | 63 (36.2) | 15 (25.0) |
| Sex | ||
| Male | 101 (58.0) | 34 (56.7) |
| Female | 73 (42.0) | 26 (43.3) |
| Immunologic phenotype | ||
| B-cell | 143 (82.2) | 42 (70.0) |
| T-cell | 31 (17.8) | 18 (30.0) |
| Lymphoma histology | ||
| Diffuse large B-cell | 98 (56.3) | 41 (68.3) |
| Transformed indolent | 38 (21.8) | 0 (0) |
| Anaplastic large cell (ALK-positive or negative) | 13 (7.5) | 4 (6.7) |
| Peripheral T-cell | 9 (5.2) | 11 (18.3) |
| Angioimmunoblastic T-cell | 9 (5.2) | 3 (5.0) |
| Primary mediastinal | 7 (4.0) | 1 (1.7) |
| Ann Arbor stage | ||
| I-II | 58 (33.3) | 28 (46.7) |
| III-IV | 116 (66.7) | 32 (53.3) |
| ECOG performance status | ||
| 0 or 1 | 149 (85.6) | 50 (83.3) |
| ≥2 | 25 (14.4) | 10 (16.7) |
| B symptoms | ||
| Absence | 137 (78.7) | 47 (78.3) |
| Presence | 37 (21.3) | 13 (21.7) |
| Bulky disease | ||
| No | 144 (82.8) | 53 (88.3) |
| Yes | 30 (17.2) | 7 (11.7) |
| Bone marrow involvement | ||
| No | 153 (87.9) | 53 (88.3) |
| Yes | 21 (12.1) | 7 (11.7) |
| Serum LDH level | ||
| Normal | 80 (46.0) | 30 (50.0) |
| Increased | 86 (49.4) | 30 (50.0) |
| Unknown | 8 (4.6) | 0 (0) |
| sIPI | ||
| Low | 66 (37.9) | 25 (41.7) |
| Low-intermediate | 48 (27.6) | 19 (31.7) |
| High-intermediate or high | 52 (29.9) | 16 (26.7) |
| Unknown | 8 (4.6) | 0 (0) |
| Response to primary therapy | ||
| ≥1 y | 57 (32.8) | 19 (31.7) |
| <1 y or refractory disease | 117 (67.2) | 41 (68.3) |
| Specific primary treatment | ||
| Previous rituximab | 135 (77.6) | 42 (70.0) |
| Previous radiotherapy | 30 (17.2) | 6 (10.0) |
| Salvage chemotherapy before ASCT | ||
| GDP | 150 (86.2) | 14 (23.3) |
| CHOP | 10 (5.7) | 0 (0) |
| DHAP | 4 (2.3) | 2 (3.3) |
| DICEP | 2 (1.1) | 0 (0) |
| ICE | 0 (0) | 34 (56.7) |
| 2 or more salvage regimens | 8 (4.6) | 10 (16.7) |
| CD20 mAb during salvage therapy | ||
| Not used | 115 (66.1) | 47 (78.3) |
| Used | 59 (33.9) | 13 (21.7) |
| Rituximab | 39 (22.4) | 13 (21.7) |
| Obinutuzumab | 20 (11.5) | 0 (0) |
| Median interval in days between PET and ASCT (range) | 20 (2-66) | 54 (6-122) |
| Median duration of follow-up (IQR), mo | 25.1 (13.9-39.4) | 38.8 (23.6-53.1) |
| Characteristic . | Training cohort (n = 174) . | Validation cohort (n = 60) . |
|---|---|---|
| Age, y | ||
| Median (range) | 55.5 (19-70) | 52.5 (20-65) |
| ≤60 | 111 (63.8) | 45 (75.0) |
| >60 | 63 (36.2) | 15 (25.0) |
| Sex | ||
| Male | 101 (58.0) | 34 (56.7) |
| Female | 73 (42.0) | 26 (43.3) |
| Immunologic phenotype | ||
| B-cell | 143 (82.2) | 42 (70.0) |
| T-cell | 31 (17.8) | 18 (30.0) |
| Lymphoma histology | ||
| Diffuse large B-cell | 98 (56.3) | 41 (68.3) |
| Transformed indolent | 38 (21.8) | 0 (0) |
| Anaplastic large cell (ALK-positive or negative) | 13 (7.5) | 4 (6.7) |
| Peripheral T-cell | 9 (5.2) | 11 (18.3) |
| Angioimmunoblastic T-cell | 9 (5.2) | 3 (5.0) |
| Primary mediastinal | 7 (4.0) | 1 (1.7) |
| Ann Arbor stage | ||
| I-II | 58 (33.3) | 28 (46.7) |
| III-IV | 116 (66.7) | 32 (53.3) |
| ECOG performance status | ||
| 0 or 1 | 149 (85.6) | 50 (83.3) |
| ≥2 | 25 (14.4) | 10 (16.7) |
| B symptoms | ||
| Absence | 137 (78.7) | 47 (78.3) |
| Presence | 37 (21.3) | 13 (21.7) |
| Bulky disease | ||
| No | 144 (82.8) | 53 (88.3) |
| Yes | 30 (17.2) | 7 (11.7) |
| Bone marrow involvement | ||
| No | 153 (87.9) | 53 (88.3) |
| Yes | 21 (12.1) | 7 (11.7) |
| Serum LDH level | ||
| Normal | 80 (46.0) | 30 (50.0) |
| Increased | 86 (49.4) | 30 (50.0) |
| Unknown | 8 (4.6) | 0 (0) |
| sIPI | ||
| Low | 66 (37.9) | 25 (41.7) |
| Low-intermediate | 48 (27.6) | 19 (31.7) |
| High-intermediate or high | 52 (29.9) | 16 (26.7) |
| Unknown | 8 (4.6) | 0 (0) |
| Response to primary therapy | ||
| ≥1 y | 57 (32.8) | 19 (31.7) |
| <1 y or refractory disease | 117 (67.2) | 41 (68.3) |
| Specific primary treatment | ||
| Previous rituximab | 135 (77.6) | 42 (70.0) |
| Previous radiotherapy | 30 (17.2) | 6 (10.0) |
| Salvage chemotherapy before ASCT | ||
| GDP | 150 (86.2) | 14 (23.3) |
| CHOP | 10 (5.7) | 0 (0) |
| DHAP | 4 (2.3) | 2 (3.3) |
| DICEP | 2 (1.1) | 0 (0) |
| ICE | 0 (0) | 34 (56.7) |
| 2 or more salvage regimens | 8 (4.6) | 10 (16.7) |
| CD20 mAb during salvage therapy | ||
| Not used | 115 (66.1) | 47 (78.3) |
| Used | 59 (33.9) | 13 (21.7) |
| Rituximab | 39 (22.4) | 13 (21.7) |
| Obinutuzumab | 20 (11.5) | 0 (0) |
| Median interval in days between PET and ASCT (range) | 20 (2-66) | 54 (6-122) |
| Median duration of follow-up (IQR), mo | 25.1 (13.9-39.4) | 38.8 (23.6-53.1) |
All data are no. (%) unless otherwise stated.
ALK, anaplastic lymphoma kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; DICEP, dose-intensive cyclophosphamide, etoposide, and cisplatin; ECOG, Eastern Cooperative Oncology Group; GDP, gemcitabine, dexamethasone, and cisplatin; ICE, ifosfamide, carboplatin, and etoposide.